NCT03821857View on ClinicalTrials.gov

Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

June 27, 2019

Primary Completion Date

May 31, 2030

Study Completion Date

May 31, 2030

Conditions
Alzheimer Disease
Interventions
DRUG

18-F-Flortaucipir

Radioligands for PET imaging of beta-amyloid and neurofibrillary tangle tau pathology

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

Mayo Clinic

OTHER